Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

Abroad (travel likely)Recruiting

Conditions

Immune-related Adverse Event · Neoadjuvant Therapy · dMMR Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Xijing hospital, Xi'an, Shaanxi, China
Contact: Study coordinator (Jipeng LI, Doctor) · jipeng1974@aliyun.com · +86-029-84771533
Contact: Study coordinator (Yihuan Qiao, Doctor) · yhqiao1995@126.com · 18682986362

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors

Cancer · Immune Checkpoint Inhibitor · Cardiovascular Complication

Abroad (travel likely)Recruiting

Paris, France

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Shenzhen, China

Brodalumab in the Treatment of Immune-Related Adverse Events

Breast Cancer · Esophageal Cancer · Kidney Cancer

Abroad (travel likely)RecruitingPHASE1

New York, United States

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Immune-Related Adverse Events

Abroad (travel likely)Recruiting

Beijing, China